

STATUS

SPECIAL AUTHORITY REQUEST THIRD-LINE ANTI-DIABETIC MEDICATIONS

received in error.

DURATION OF APPROVAL

HLTH 5481 Rev. 2022/12/07

If you have received this fax in error, please write MISDIRECTED across the front of the form and fax

toll-free to 1-800-609-4884, then destroy the pages

 $For up-to-date\ criteria\ and\ forms,\ please\ check: \underline{www.gov.bc.ca/pharmacarespecial authority}$

Fax requests to 1-800-609-4884 (toll free) OR mail requests to: PharmaCare, Box 9652 Stn Prov Govt, Victoria, BC V8W 9P4 This facsimile is doctor-patient privileged and contains confidential information intended only for PharmaCare. Any other distribution, copying or disclosure is strictly prohibited.

		st, approval is granted solely for the purpose uested medication is, or is not, suitable for a			
Forms with information missi	ng will be retur	ned for completion. If no prescriber fo	ax or mailing address is provided	, PharmaC	Care will be unable to return a response.
SECTION 1 – PRESCRIBER INFORMATION			SECTION 2 - PATIENT INFORMATION		
Name and Mailing Address			Patient (Family) Name		
			Patient (Given) Name(s)		
College ID (use ONLY College ID number) Phone Number (include area		Phone Number (include area code)	Date of Birth (YYYY / MM / DD) Date of Application (YYYY / MM / DD)		
CRITICAL FOR A TIMELY RESPONSE		ax Number	CRITICAL FOR PROCESSING Personal Health Number (PHN)		Health Number (PHN)
SECTION 3 - MEDICAT	ION REQU	ESTED			
Oipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) 9901-0073			O Pioglitazone 9901-0361		
		ormin Combination Tablet formin Combination Tablet			
	a DPP-4 inhibi	nagliptin or saxagliptin) is not provided tor will be discontinued if applicable. It ble.			
SECTION 4 - CRITERIA	FOR INDE	FINITE COVERAGE			
As part of THIRD-LINE combir	ation treatmen	t for type 2 diabetes mellitus AFTER ina	adequate glycemic control on ma	ximally tol	erated doses of:
A. O Dual therapy of me	etformin and a	sulfonylurea			
OR B. O Dual therapy of mo	etformin and ar	n insulin			
Please provide rationale for a	voiding above t	rials if applicable:			
Report all adverse events	s to the post-	market surveillance program, Ca	anadian Vigilance, toll-free 1	-866-234	4-2345 (health professionals only).
Personal information on this form is collected under the authority of, and in accordance with, the <i>British Columbia Pharmaceutical Services Act</i> 22(1) and <i>Freedom of Information and Protection of Privacy Act</i> 26 (a),(c),(e). The information is being collected for the purposes of (a) administering the PharmaCare program, (b) analyzing, planning and evaluating the Special Authority and other Ministry programs and (c) to manage and plan for the health system generally. If you have any questions about the collection of this information, call Health Insurance BC from Vancouver at 1-604-683-7151 or from elsewhere in BC toll free at 1-800-663-7100 and ask to consult a pharmacist concerning the Special Authority process.			I have discussed with the patient that the purpose of releasing their information to PharmaCare is to obtain Special Authority for prescription		
			coverage and for the purpo	oses set o	ut here.
			Prescriber's Signature (Mandatory)		
		ation to support this Special Authority re nd to any other applicable PharmaCare p		ect to the r	ules of a patient's PharmaCare plan,
PHARMACARE USE OI	NLY				

EFFECTIVE DATE (YYYY / MM / DD)